ARS Pharmaceuticals 1Q 2026: Revenue $22.7M, EPS $(0.61) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.
ARS Pharmaceuticals reported Q1 2026 revenue of $22.7M, a 184% increase from $8M in Q1 2025. However, the net loss widened to $60.6M, with diluted EPS at $(0.61). Product revenue rose to $17.5M, and the company is scaling its U.S. launch with 148 sales reps. Over 28,000 prescribers and 120,000 patients are using neffy, with payer coverage near 90%. Operational scale-up is ongoing with regulatory approvals in multiple markets.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments